This technology is an anti-allergic pharmaceutical composition containing ZAG (Zinc-alpha-2-glycoprotein) as an active ingredient, based on its ability to activate the expression of filaggrin, a key protein in the skin barrier. It includes formulations designed for topical application.
Topical steroids, calcineurin inhibitors, oral steroids, and immunomodulators have been difficult to use long-term due to irritation or systemic side effects. Moisturizer-based therapies have also been limited in their inability to reverse the reduction of filaggrin, a primary cause of skin barrier damage.
This technology utilizes ZAG to promote filaggrin production, aiding skin barrier recovery while regulating histamine, inflammatory cytokines, and regulatory T-cell levels. Applicable to treatments for atopic dermatitis, urticaria, and allergic rhinitis, as well as barrier-strengthening topicals, it offers a recovery-focused therapeutic strategy that goes beyond mere symptom suppression.
N/A
